On November 23, 2015, the U.S. Food and Drug Administration approved the new use of a vaccine called BioThrax. It is to be used in conjunction with an antibiotic to treat persons between 18 and 65 years old who have been infected by anthrax.
The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.
FDA News Release: FDA approves vaccine for use after known or suspected anthrax exposure. November 23, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474027.htm
Go to article
Posts on this page are compiled from information Region 7 receives form partners and related news media resources.